Diagnostic Values of Galectin-3, Soluble ST2 and BNP in Predicting the Clinical Outcome of ST-Segment Elevation Myocardial Infarction Patients

NCT ID: NCT05246215

Last Updated: 2022-02-18

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 90 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-03-01
• Study Completion Date: 2026-03-01

Brief Summary

An acute ST-elevation myocardial infarction occurs due to occlusion of one or more coronary arteries, causing transmural myocardial ischemia which in turn results in myocardial injury or necrosis. Acute myocardial infarction (AMI) may lead to the development of heart failure (HF). Accessible diagnostic tools commonly used in HF such as natriuretic peptides and (NYHA) classification reflect already overt clinical HF. Troponin and creatine kinase reflect myocardial damage, but their usefulness in predicting long-term LVR is limited. Recent guidelines on HF management stressed that HF onset may be delayed or prevented through certain Interventions, such as pharmacotherapy ,post infarction rehabilitation, or modification of HF risk factors. Therefore, it is important to identify potential markers, which would be more informative of HF preclinical stages to recognize patients with an increased risk of HF onset, and to start treatment in advance (1) Gal-3 participates in inflammation and pro fibrotic pathways, while sST2 is a biomarker of inflammation, cardiac mechanical strain, and tissue fibrosis, both of which may predict LVR (2).

sST is a biomarker of inflammation, cardiac mechanical strain, and tissue fibrosis(3).

B_type natriuretic peptide (BNP) is elevated in acute myocardial infarction and is a quantitative biochemical marker related to the extent of infarction and left ventricular systolic dysfunction(4).

Conditions

ST Elevation Myocardial Infarction; HF - Heart Failure; Stable Angina

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

STEMI group.

60 participants of patients with STEMI treated with primary percutaneous coronary intervention (pPCI).

No interventions assigned to this group

healthy group.

15 participants of healthy people as a case control.

No interventions assigned to this group

Stable angina group.

15 participants of patients stable angina

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18 years.

2. Hospital admission due to first-time STEMI treated with pPCI.

Exclusion Criteria

• History of previous acute coronary syndrome, Previously diagnosed HF or asymptomatic LV dysfunction with LVEF <50% or previously diagnosed significant valvular disease or any other previously diagnosed structural heart disease Severe renal dysfunction, Severe liver disease, Chronic inflammatory disease, Current neoplastic disease

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Assiut University

OTHER

Sponsor Role: lead

Responsible Party

Aya Khalifa Mohamed Abdelzaher

Resident doctor.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Central Contacts

Aya Khalifa Abdelzaher

Role: CONTACT

aya.khalifa150@hotmail.com

+201158166015

Other Identifiers

DV_Gal_3,sST2

Identifier Type: -

Identifier Source: org_study_id